Development of amidase-dependent pyrazinoic acid prodrugs with activity against pyrazinamide resistant Mycobacterium tuberculosis
C. Levine, R. Jadhav, P. Yan, K. Tsotetsi, X. Wang, D. Awasthi, C. Grady, A. Shelke, S. S. Daher, T. Richmann, R. Shrestha, P. Sukheja, J. Patel, P. R. Barnett, R. J. Dikdan, , P. Kumar
This paper develops amidase-dependent pyrazinoic acid prodrugs that bypass PncA activation, showing efficacy against PZA-resistant Mtb.
bioRxiv · Jul 5, 2022 · PreprintMicrobiology